DEVELOPMENT AND VALIDATION OF A SIMPLE, RAPID AND ROBUST RP-HPLC METHOD FOR THE ESTIMATION OF MOLNUPIRAVIR IN BULK DRUG AND MARKETED CAPSULE FORMULATION

Background: Molnupiravir is an orally active antiviral nucleoside analogue prodrug used for the management of COVID-19. The development of a reliable, rapid and reproducible analytical method is essential for the quality control of Molnupiravir bulk drug and pharmaceutical formulations. Objective: The present study aimed to develop and validate a reverse-phase high-performance liquid chromatographic (RP-HPLC) method for the quantitative determination of Molnupiravir in bulk drug and marketed capsule formulation. Methods: Chromatographic separation of Molnupiravir was performed using a reversed-phase C18 analytical column. The developed method was evaluated for system suitability, linearity, accuracy, precision, robustness, ruggedness, limit of detection (LOD), limit of quantification (LOQ), and assay of the marketed formulation in accordance with analytical method-validation principles. Linearity was evaluated over 10–50 µg/mL. Accuracy was investigated at 80%, 100%, and 120% concentration levels. Precision was evaluated through repeatability and intra-day/inter-day studies. Results: The developed method exhibited satisfactory chromatographic performance with a retention time of approximately 3.6 min. The calibration response was evaluated over 10–50 µg/mL. The LOD and LOQ were found to be 0.4548 and 1.3782 µg/mL, respectively. Recovery studies were within 98–102%. Repeatability demonstrated 101.34% mean assay with %RSD of 1.44. Analysis of Molnatris® 200 mg capsules showed 99.51% label claim with %RSD of 0.064. Ruggedness studies using different analysts showed acceptable reproducibility. Conclusion: The developed RP-HPLC method demonstrated satisfactory linearity, accuracy, precision, sensitivity, robustness and ruggedness and can be considered suitable for routine quantitative analysis of Molnupiravir in bulk drug and marketed capsule formulation.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Delivery Technology
Published
2026-11-17
DOI
https://doi.org/10.25258/ijddt.16.80s.108
Primary Topic
Analytical Methods in Pharmaceuticals
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DEVELOPMENT AND VALIDATION OF A SIMPLE, RAPID AND ROBUST RP-HPLC METHOD FOR THE ESTIMATION OF MOLNUPIRAVIR IN BULK DRUG AND MARKETED CAPSULE FORMULATION

Rupesh Pingale, Gouri Palsokar, Gaurav Subhash Gosavi
International Journal of Drug Delivery Technology
Analytical Methods in Pharmaceuticals
article

DEVELOPMENT AND VALIDATION OF A SIMPLE, RAPID AND ROBUST RP-HPLC METHOD FOR THE ESTIMATION OF MOLNUPIRAVIR IN BULK DRUG AND MARKETED CAPSULE FORMULATION

Rupesh Pingale, Gouri Palsokar, Gaurav Subhash Gosavi
article en

Abstract

Background: Molnupiravir is an orally active antiviral nucleoside analogue prodrug used for the management of COVID-19. The development of a reliable, rapid and reproducible analytical method is essential for the quality control of Molnupiravir bulk drug and pharmaceutical formulations. Objective: The present study aimed to develop and validate a reverse-phase high-performance liquid chromatographic (RP-HPLC) method for the quantitative determination of Molnupiravir in bulk drug and marketed capsule formulation. Methods: Chromatographic separation of Molnupiravir was performed using a reversed-phase C18 analytical column. The developed method was evaluated for system suitability, linearity, accuracy, precision, robustness, ruggedness, limit of detection (LOD), limit of quantification (LOQ), and assay of the marketed formulation in accordance with analytical method-validation principles. Linearity was evaluated over 10–50 µg/mL. Accuracy was investigated at 80%, 100%, and 120% concentration levels. Precision was evaluated through repeatability and intra-day/inter-day studies. Results: The developed method exhibited satisfactory chromatographic performance with a retention time of approximately 3.6 min. The calibration response was evaluated over 10–50 µg/mL. The LOD and LOQ were found to be 0.4548 and 1.3782 µg/mL, respectively. Recovery studies were within 98–102%. Repeatability demonstrated 101.34% mean assay with %RSD of 1.44. Analysis of Molnatris® 200 mg capsules showed 99.51% label claim with %RSD of 0.064. Ruggedness studies using different analysts showed acceptable reproducibility. Conclusion: The developed RP-HPLC method demonstrated satisfactory linearity, accuracy, precision, sensitivity, robustness and ruggedness and can be considered suitable for routine quantitative analysis of Molnupiravir in bulk drug and marketed capsule formulation.

International Journal of Drug Delivery TechnologyVol. 16(80s)
Sterling Research Group (US)
Good health and well-being
Analytical Methods in Pharmaceuticals
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon